ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+25.71%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$156M
AUM Growth
+$156M
(+19%)
Cap. Flow
+$18M
Cap. Flow
% of AUM
11.57%
Top 10 Holdings %
Top 10 Hldgs %
52.92%
Holding
50
New
18
Increased
7
Reduced
9
Closed
16
Top Buys
| 1 |
Insulet
PODD
|
$9.74M |
| 2 |
QuidelOrtho
QDEL
|
$8.63M |
| 3 |
Standard BioTools
LAB
|
$7.27M |
| 4 |
Illumina
ILMN
|
$6.32M |
| 5 |
Kura Oncology
KURA
|
$6.14M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$5.95M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$5.79M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$5.3M |
| 4 |
Centene
CNC
|
$4.92M |
| 5 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
$4.5M |
Sector Composition
| 1 | Healthcare | 97.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $12.6M | 8.08% | 81,442 +33,843 | +71% | +$5.22M |
|
|
2
Insulet
PODD
$23.9B
| $9.74M | 6.26% | +41,147 | New | +$9.74M |
|
|
3
QuidelOrtho
QDEL
$1.95B
| $8.63M | 5.54% | +39,314 | New | +$8.63M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $8.56M | 5.5% | 155,232 -16,084 | -9% | -$887K |
|
5
Guardant Health
GH
$8.41B
| $7.7M | 4.95% | 68,863 -27,176 | -28% | -$3.04M |
|
6
Cytokinetics
CYTK
$4.23B
| $7.37M | 4.73% | 340,253 +134,167 | +65% | +$2.9M |
|
|
7
Standard BioTools
LAB
$481M
| $7.27M | 4.67% | +978,158 | New | +$7.27M |
|
|
NSTG
8
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.21M | 4.63% | 161,253 -58,324 | -27% | -$2.61M |
|
|
ARNA
9
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.98M | 4.49% | 93,308 -79,588 | -46% | -$5.95M |
|
|
10
Illumina
ILMN
$15.8B
| $6.32M | 4.06% | +20,451 | New | +$6.32M |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $6.26M | 4.03% | 102,462 -94,787 | -48% | -$5.79M |
|
|
12
Kura Oncology
KURA
$686M
| $6.14M | 3.95% | +200,484 | New | +$6.14M |
|
13
UnitedHealth
UNH
$281B
| $5.82M | 3.74% | 18,666 +5,762 | +45% | +$1.8M |
|
|
BNR
14
Burning Rock Biotech
BNR
$93.6M
| $5.45M | 3.5% | +217,362 | New | +$5.45M |
|
15
10x Genomics
TXG
$1.74B
| $5.43M | 3.49% | 43,512 -7,307 | -14% | -$911K |
|
16
Fate Therapeutics
FATE
$120M
| $4.53M | 2.91% | 113,366 +4,201 | +4% | +$168K |
|
|
HZNP
17
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.04M | 2.6% | +51,995 | New | +$4.04M |
|
18
Forte Biosciences
FBRX
$137M
| $3.87M | 2.49% | +79,823 | New | +$3.87M |
|
|
BMY.RT
19
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $3.51M | 2.26% | 1,560,327 -1,997,719 | -56% | -$4.5M |
|
|
ATRS
20
DELISTED
Antares Pharma, Inc.
ATRS
| $3.23M | 2.07% | 1,194,530 -104,672 | -8% | -$283K |
|
|
TPTX
21
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $3.2M | 2.05% | 36,571 +13,963 | +62% | +$1.22M |
|
|
NCNA
22
NuCana
NCNA
$6.09M
| $2.66M | 1.71% | 514,122 +343,135 | +201% | +$1.77M |
|
|
AVDL
23
Avadel Pharmaceuticals
AVDL
$1.43B
| $2.63M | 1.69% | 520,830 -12,802 | -2% | -$64.5K |
|
24
Pacific Biosciences
PACB
$393M
| $2.54M | 1.63% | +257,044 | New | +$2.54M |
|
25
MEI Pharma
MEIP
$160M
| $2.46M | 1.58% | +787,359 | New | +$2.46M |
|